Market Analysts see Recursion Pharmaceuticals Inc [RXRX] gaining to $8. Time to buy?

- Advertisements -

Recursion Pharmaceuticals Inc [NASDAQ: RXRX] stock went on an upward path that rose over 10.49% on Tuesday, amounting to a one-week price increase of more than 15.72%. The company report on November 2, 2023 at 8:05 AM that Recursion to Participate in Upcoming Investor Conference.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference:.

- Advertisements -

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Over the last 12 months, RXRX stock dropped by -36.62%. The one-year Recursion Pharmaceuticals Inc stock forecast points to a potential upside of 61.81. The average equity rating for RXRX stock is currently 2.14, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.29 billion, with 183.21 million shares outstanding and 138.42 million shares in the current float. Compared to the average trading volume of 3.59M shares, RXRX stock reached a trading volume of 5477180 in the most recent trading day, which is why market watchdogs consider the stock to be active.

- Advertisements -

Guru’s Opinion on Recursion Pharmaceuticals Inc [RXRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RXRX shares is $16.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RXRX stock is a recommendation set at 2.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Recursion Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on May 22, 2023.

The Average True Range (ATR) for Recursion Pharmaceuticals Inc is set at 0.45, with the Price to Sales ratio for RXRX stock in the period of the last 12 months amounting to 25.87. The Price to Book ratio for the last quarter was 2.64, with the Price to Cash per share for the same quarter was set at 1.93.

- Advertisements -

RXRX Stock Performance Analysis:

Recursion Pharmaceuticals Inc [RXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.72. With this latest performance, RXRX shares dropped by -9.62% in over the last four-week period, additionally plugging by 6.08% over the last 6 months – not to mention a drop of -36.62% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RXRX stock in for the last two-week period is set at 48.20, with the RSI for the last a single of trading hit 55.29, and the three-weeks RSI is set at 44.49 for Recursion Pharmaceuticals Inc [RXRX]. The present Moving Average for the last 50 days of trading for this stock 7.18, while it was recorded at 5.57 for the last single week of trading, and 8.03 for the last 200 days.

Insight into Recursion Pharmaceuticals Inc Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Recursion Pharmaceuticals Inc [RXRX] shares currently have an operating margin of -616.74 and a Gross Margin at -22.11. Recursion Pharmaceuticals Inc’s Net Margin is presently recorded at -601.05.

Return on Total Capital for RXRX is now -45.04, given the latest momentum, and Return on Invested Capital for the company is -44.20. Return on Equity for this stock declined to -46.56, with Return on Assets sitting at -36.52. When it comes to the capital structure of this company, Recursion Pharmaceuticals Inc [RXRX] has a Total Debt to Total Equity ratio set at 10.50. Additionally, RXRX Total Debt to Total Capital is recorded at 9.50, with Total Debt to Total Assets ending up at 7.27. Long-Term Debt to Equity for the company is recorded at 9.25, with the Long-Term Debt to Total Capital now at 8.37.

Receivables Turnover for the company is 6.73 with a Total Asset Turnover recorded at a value of 0.06.Recursion Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.72 and a Current Ratio set at 3.72.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Recursion Pharmaceuticals Inc go to 12.00%.

Recursion Pharmaceuticals Inc [RXRX] Institutonal Ownership Details

The top three institutional holders of RXRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in RXRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in RXRX stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *